Sage Therapeutics Inc
SAGE
Company Profile
Business description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Contact
55 Cambridge Parkway
CambridgeMA02142
USAT: +1 617 299-8380
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
487
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,225.10 | 58.40 | 0.72% |
| CAC 40 | 8,108.59 | 86.26 | 1.08% |
| DAX 40 | 23,109.79 | 257.13 | 1.13% |
| Dow JONES (US) | 42,587.50 | 4.18 | 0.01% |
| FTSE 100 | 8,663.80 | 25.79 | 0.30% |
| HKSE | 23,447.49 | 103.24 | 0.44% |
| NASDAQ | 18,271.86 | 83.26 | 0.46% |
| Nikkei 225 | 38,027.29 | 246.75 | 0.65% |
| NZX 50 Index | 12,334.18 | 149.67 | 1.23% |
| S&P 500 | 5,776.65 | 9.08 | 0.16% |
| S&P/ASX 200 | 7,999.00 | 56.50 | 0.71% |
| SSE Composite Index | 3,369.56 | 0.42 | -0.01% |